Skip to Content
Merck

L0376000

Leuprorelin

European Pharmacopoeia (EP) Reference Standard

Sign In to View Organizational & Contract Pricing.

Select a Size

All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C59H84N16O12
CAS Number:
53714-56-0
Molecular Weight:
1209.40
UNSPSC Code:
41116107
NACRES:
NA.24

Product Name

Leuprorelin, European Pharmacopoeia (EP) Reference Standard

SMILES string

[nH]1cncc1C[C@H](NC(=O)C6NC(=O)CC6)C(=O)N[C@@H](Cc4c5c([nH]c4)cccc5)C(=O)NC(CO)C(=O)N[C@@H](Cc3ccc(cc3)O)C(=O)N[C@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N2[C@@H](CCC2)C(=O)NCC.OC(=O)C

InChI

1S/C57H80N16O12.C2H4O2/c1-6-61-53(82)44-14-10-22-73(44)56(85)39(13-9-21-62-57(58)59)66-54(83)46(30(2)3)72-55(84)47(31(4)5)71-51(80)40(23-32-15-17-35(75)18-16-32)67-52(81)43(28-74)70-49(78)41(24-33-26-63-37-12-8-7-11-36(33)37)68-50(79)42(25-34-27-60-29-64-34)69-48(77)38-19-20-45(76)65-38;1-2(3)4/h7-8,11-12,15-18,26-27,29-31,38-44,46-47,63,74-75H,6,9-10,13-14,19-25,28H2,1-5H3,(H,60,64)(H,61,82)(H,65,76)(H,66,83)(H,67,81)(H,68,79)(H,69,77)(H,70,78)(H,71,80)(H,72,84)(H4,58,59,62);1H3,(H,3,4)/t38?,39-,40-,41-,42-,43?,44-,46-,47+;/m0./s1

InChI key

ATCUBNJYGKGZGL-GZROYGCLSA-N

grade

pharmaceutical primary standard

API family

leuprorelin

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

Related Categories

Application

This European Pharmacopoeia reference standard is intended for use only as specifically prescribed in the European Pharmacopoeia. Their suitability for any other use is not guaranteed and is the sole responsibility of the user. This standard is not intended for human or animal use.
Established for the preparation of reference solutions (a) in the assay and testing of related substances of leuprorelin using liquid chromatography (General text 2.2.29), according to the monograph 1442 of European Pharmacopeia.

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets, has been developed and issued under the Authority of the Issuing Pharmacopoeia.

For further information and support please go to the website of the issuing Pharmacopoeia.

It is a synthetic nonapeptide analogue of the hypothalamic peptide, gonadorelin. It is obtained by chemical synthesis and is available as an acetate.

Other Notes

Sales restrictions may apply.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Piero Periti et al.
Clinical pharmacokinetics, 41(7), 485-504 (2002-06-27)
Leuprorelin acetate is a synthetic agonist analogue of gonadotropin-releasing hormone. Continued leuprorelin administration results in suppression of gonadal steroid synthesis, resulting in pharmacological castration. Since leuprorelin is a peptide, it is orally inactive and generally given subcutaneously or intramuscularly. Sustained
R Berges et al.
Current medical research and opinion, 22(4), 649-655 (2006-05-11)
Leuprorelin is a well known luteinising hormone releasing hormone (LHRH) agonist. The drug is effective in the treatment of advanced prostate cancer and is well tolerated. This article reviews published literature (based on a search of PubMed, EMBASE and Biosis
Leuprorelin
European Pharmacopoeia Commission and European Directorate for the Quality of Medicines & Healthcare
European pharmacopoeia, 3073-3074 (2008)
K Yasukawa et al.
The British journal of dermatology, 152(5), 1045-1047 (2005-05-13)
Leuprorelin acetate, an agonist of gonadotropin-releasing hormone (GnRH), is indicated in the treatment of prostate cancer. Recently, depot formulations of leuprorelin acetate have been widely used. We report three patients who showed a granulomatous reaction after treatment using a leuprorelin
G L Plosker et al.
Drugs, 48(6), 930-967 (1994-12-01)
Leuprorelin (leuprolide acetate) is a gonadotrophin-releasing hormone (GnRH) analogue used to treat a wide range of sex hormone-related disorders including advanced prostatic cancer, endometriosis and precocious puberty. It acts primarily on the anterior pituitary, inducing a transient early rise in
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service